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Abstract 
Background/objective: Multivariable prognostic scores play an important role for clinical decision-making, informa-
tion giving to patients/relatives, benchmarking and guiding clinical trial design. Coagulopathy has been implicated 
on trauma and critical care outcomes, but few studies have evaluated its role on traumatic brain injury (TBI) outcomes. 
Our objective was to verify the incremental prognostic value of routine coagulopathy parameters in addition to the 
CRASH-CT score to predict 14-day mortality in TBI patients.
Methods: This is a prospective cohort of consecutive TBI patients admitted to a tertiary university hospital Trauma 
intensive care unit (ICU) from March/2012 to January/2015. The prognostic performance of the coagulation param-
eters platelet count, prothrombin time (international normalized ratio, INR) and activated partial thromboplastin time 
(aPTT) ratio was assessed through logistic regression adjusted for the original CRASH-CT score. A new model, CRASH-
CT-Coag, was created and its calibration (Brier scores and Hosmer–Lemeshow (H–L) test), discrimination [area under 
the receiver operating characteristic curve (AUC-ROC) and the integrated discrimination improvement (IDI)] and clini-
cal utility (net reclassification index) were compared to the original CRASH-CT score.
Results: A total 517 patients were included (median age 39 years, 85.1% male, median admission glasgow coma 
scale 8, neurosurgery on 44.9%). The 14-day mortality observed and predicted by the original CRASH-CT was 22.8% 
and 26.2%, respectively. Platelet count < 100,000/mm3, INR > 1.2 and aPTT ratio > 1.2 were present on 11.3%, 65.0% and 
27.2%, respectively, (at least one of these was altered on 70.6%). All three variables maintained statistical significance 
after adjustment for the CRASH-CT score. The CRASH-CT-Coag score outperformed the original score on calibration 
(brier scores 0.122 ± 0.216 vs 0.132 ± 0.202, mean difference 0.010, 95% CI 0.005–0.019, p = 0.036, respectively) and 
discrimination (AUC-ROC 0.854 ± 0.020 vs 0.813 ± 0.024, p = 0.014; IDI 5.0%, 95% CI 1.3–11.0%). Both scores showed 
the satisfactory H–L test results. The net reclassification index favored the new model. Considering the strata of low 
(< 10%), moderate (10–30%) and high (> 30%) risk of death, the CRASH-CT-Coag model yielded a global net correct 
reclassification of 22.9% (95% CI 3.8–43.4%).
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Introduction
Multivariable prognostic scores are the key not only for 
therapeutic management and clinical decision-making, 
but also to reliably inform patients and relatives, to guide 
trials design and for benchmarking the quality of care 
by comparing observed and expected outcomes [1]. The 
corticosteroid randomization after significant head injury 
(CRASH) score is one of the main validated prognostic 
models for traumatic brain injury (TBI) [2, 3]. These and 
other TBI prognostic scores have underevaluated coagu-
lopathy markers, which have been implicated on trauma 
and critical care patients’ outcomes.
Few studies have evaluated the role of coagulopathy 
markers on TBI outcomes, and most of them have not 
performed an analysis adjusted for already-validated 
prognostic scores [4, 5]. Only one study has formally 
evaluated the incremental prognostic value of coagulopa-
thy in addition to a well-grounded prognostic score [6]. 
Indeed, coagulopathy improved the discrimination abil-
ity of the model by increasing its area under the receiver 
operating characteristic curve (AUC-ROC); however, the 
calibration and clinical utility (net reclassification index, 
NRI) of the new model were not fully assessed.
Here, we aimed to verify the incremental prognos-
tic value (discrimination, calibration and clinical utility) 
of routine hospital admission coagulopathy parameters 
(platelet count, prothrombin time and activated partial 
thromboplastin time) in addition to the CRASH score to 
predict 14-day mortality outcome in TBI patients.
Materials and Methods
This is a prospective cohort that included consecutive 
TBI patients admitted to a trauma intensive care unit 
(ICU) of a tertiary university hospital (Hospital das Clíni-
cas da Faculdade de Medicina da Universidade de São 
Paulo—HC/FMUSP) from March 2012 to January 2015. 
Patients under 14 years old, victims of penetrating TBI or 
admitted from another ICU were excluded. Chronic sub-
dural hematomas were also excluded.
Clinical, laboratory and radiological data were reg-
istered, as well as the primary outcome, 14-day death. 
Clinical predictors were defined as recommended by the 
brain trauma foundation and similar to the CRASH study 
protocol, including the definitions of major extracranial 
injury and head computed tomography (CT) altera-
tions [2, 7]. Imaging (head computed tomography) was 
reviewed by a neurosurgeon blinded to the clinical data. 
Laboratory variables were registered at hospital admis-
sion, thus prior to the primary outcome. The percentages 
of missing data were: pupil reactivity at admission 5.8%; 
admission Glasgow coma scale (GCS) 5.0%; extracranial 
lesion at admission 1.2%; and age 1.2%. Since the original 
CRASH-CT score exact risk probability for each patient 
was crucial for the study objective and analysis, we 
decided not to execute multiple imputation and to per-
form a complete-case analysis.
The study protocol was approved by the local eth-
ics committee (Comissão de Análise de Projetos de 
Pesquisa—CAPPesq, HC/FMUSP, protocol number 
00119/10).
Statistical Analysis
Categorical variables were described as absolute and rela-
tive frequencies and compared through the χ2 test or the 
Fisher exact test, as appropriate. Continuous variables 
distributions were evaluated by skewness and kurtosis 
values as well as graphical methods. Those with normal 
distributions were described as means and standard devi-
ations and compared through the independent samples 
Student T test. The ones with non-normal distributions 
were described as medians and quartiles and compared 
through the Mann–Whitney test.
The performance of the coagulation parameters as 
predictors of 14-day death was assessed through logis-
tic regression analysis with adjustment for the original 
CRASH-CT score. Platelet count, prothrombin time 
(international normalized ratio, INR) and activated par-
tial thromboplastin time (aPTT, ratio) were included as 
binary variables for the sake of clinical utility: Platelet 
count was deemed low if < 100,000/mm3; INR was con-
sidered altered if > 1.2; and aPTT was considered abnor-
mal if its ratio was > 1.2. Only cases with complete data 
for the CRASH-CT score calculations were included 
in the respective models. Data regarding pre-hospital 
hypoxia or admission glucose was missing for almost 
half of the cohort, so we were not able to perform the 
same analysis with adjustment to the extended IMPACT 
model.
A new model, CRASH-CT-Coag, was created after 
the above-cited logistic regression adjustment and, 
thus, included the original CRASH-CT score, platelet 
count, INR and aPTT ratio. The latter covariates, the 
Conclusions: The addition of early markers of coagulopathy—platelet count, INR and aPTT ratio—to the CRASH-CT 
score increased its accuracy. Additional studies are required to externally validate this finding and further investigate 
the coagulopathy role on TBI outcomes.
Keywords: Traumatic brain injury, Coagulopathy, Prognosis, Prognostic score, Mortality
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coagulation parameters, were included as binary vari-
ables (altered or normal). The CRASH-CT-Coag accu-
racy was compared to the original CRASH-CT score. 
The calibration was evaluated by the Hosmer–Lemeshow 
goodness-of-fit test, which compares the predicted and 
observed death probabilities in each risk decile, and by 
the Brier scores, a measure of the mean squared devia-
tion between the predicted death probabilities and the 
observed outcomes. The discrimination was evaluated 
by the respective areas under the receiver operating 
characteristic curve (AUC-ROC), which were compared 
through the DeLong method, and by the integrated dis-
crimination improvement (IDI), a measure of the dif-
ference in predicted death probabilities between the 
survivors and dead subjects. The clinical utility of the 
new prognostic model was evaluated by the net reclassifi-
cation index (NRI). The NRI calculation had the assump-
tion of the following death risk stratification: low (< 10%), 
moderate (10–30%) and high (> 30%) risk. The decision 
for this death risk stratification was empirical, but other 
stratification schemes were explored and generally lead 
to similar conclusions. Bootstrap sampling (1000 sam-
ples) was employed for the calculation of point estimates, 
standard errors and confidence intervals (CI). The statis-
tical analysis flowchart is depicted in Fig. 1.
All tests were two-tailed, and final p values < 0.05 were 
considered statistically significant. These were the soft-
wares employed for the analysis: R (R Core Team. R: A 
language and environment for statistical computing. 
R Foundation for Statistical Computing, Vienna, Aus-
tria), SPSS (IBM Corp. SPSS Statistics para Windows, 
versão 24.0. Armonk, NY) and MedCalc Statistical Soft-
ware (MedCalc Software bvba, versão 15.2.0.0. Ostend, 
Belgium). The transparent reporting of a multivariable 
prediction model for individual prognosis or diagnosis 
(TRIPOD) statement was followed for this study report.
Results
A total of 517 patients were included, with a median 
age of 39 (quartiles 27–52) years and 85.1% male. The 
three most common trauma mechanisms were fall from 
height (30.1%), fall from own height (26.1%) and motor-
cycle accident (19.5%). The median admission GCS was 8 
(6–13), and pupil reactivity was absent/sluggish unilater-
ally on 12.9% and bilaterally on 5.9%. Major extracranial 
lesion was present on 54.4%, and neurosurgery was per-
formed on 44.9% of the patients. These data and the head 
CT findings are summarized in Table 1. The mean 14-day 
death probability predicted by the original CRASH-CT 
score was 26.2%, and the in-hospital death probability 
predicted by the SAPS3 score was 26.4%. The observed 
14-day and in-hospital death were 22.8% and 30.9%, 
respectively. The CRASH-CT score was available for 452 
patients, with similar characteristics compared to the full 
cohort.
Thrombocytopenia, INR > 1.2 and aPTT > 1.2 were pre-
sent on 11.3%, 65.0% and 27.2%, respectively. At least one 
of these parameters was altered on 70.6%. The univariate 
Fig. 1 Statistical analysis flowchart
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analyses for the coagulation parameters are presented 
in Table  2. Platelet count, prothrombin time and aPTT 
levels were associated with 14-day outcome. Platelet 
count was lower, and thrombocytopenia (< 100,000/
mm3) was more common on the subgroup that evolved 
to death. Similarly, INR and aPTT were higher and more 
commonly altered (> 1.2) on this subgroup. These results 
were the same for the subset with the CRASH-CT score 
available (data not shown).
The three coagulation parameters of interest were 
included as binary variables (normal or altered) on 
the multivariable logistic regression analyses. Platelet 
Table 1 Study sample characterization
Categorical data are presented as n (%) and continuous data as median (quartiles) or mean ± standard deviation
SAH subarachnoid hemorrhage, SAPS3 simplified acute physiology score 3, VT ventricle
Variables Full cohort (517) CRASH-CT 
available 
(452)
Age (years) 39 (27–52) 38 (26–51)
Male gender 440 (85.1) 387 (85.6)
Trauma mechanism
 Fall from height 156 (30.2) 141 (31.2)
 Fall from own height 135 (26.1) 117 (25.9)
 Motorcycle accident 101 (19.5) 89 (19.7)
 Car accident 55 (10.6) 49 (10.8)
 Other 70 (13.5) 56 (12.4)
Glasgow coma scale 8 (6–13) 8 (6–13)
 Motor score 5 (4–6) 5 (4–6)
Pupil reactivity
 None 29 (6.0) 26 (5.8)
 One 63 (12.9) 59 (13.1)
 Both 395 (81.1) 367 (81.2)
Major extracranial lesion 278 (54.4) 255 (56.4)
Head computed tomography
 Marshall classification
  I 21 (4.1) 18 (4.0)
  II 215 (41.6) 196 (43.4)
  III 43 (8.3) 36 (8.0)
  IV 21 (4.1) 20 (4.4)
  V 211 (40.8) 178 (39.4)
  VI 6 (1.2) 4 (0.9)
 Hemorrhagic petechiae 70 (13.5) 62 (13.7)
 Compressed III VT or basal cisterns 90 (17.4) 71 (15.7)
 Traumatic SAH 465 (89.9) 403 (89.2)
 Midline shift > 5 mm 153 (29.6) 128 (28.3)
 Hematoma 342 (66.2) 292 (64.6)
 Effaced cortical sulci 224 (43.3) 192 (42.5)
 Intraventricular hemorrhage 112 (21.7) 98 (21.7)
 Skull fracture 263 (50.9) 233 (51.5)
 Surgically evacuated hematoma 232 (44.9) 197 (43.6)
Prognostic scores
 CRASH-CT model 14-day death probability (%) – 26.2 ± 22.9
 SAPS 3 for in-hospital death (points) 51.3 ± 15.4 51.0 ± 14.9
Mortality
 Fourteen-day 118 (22.8) 99 (21.9)
 In-hospital 160 (30.9) 132 (29.2)
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count below 100,000/mm3 (OR 2.45, 95% CI 1.14–5.25, 
p = 0.021), INR above 1.2 (OR 2.03, 95% CI 1.05–3.94, 
p = 0.036) and aPTT ratio above 1.2 (OR 2.50, 95% CI 
1.41–4.48, p = 0.002) maintained statistical significance 
after adjustment for the CRASH-CT score. More details 
of the multivariable model are presented in Table 3.
As stated on the methods section, a new model, 
CRASH-CT-Coag, was created and compared to the 
original CRASH-CT model regarding calibration, dis-
crimination and clinical utility. The mean 14-day death 
probability predicted by the CRASH-CT-Coag was 22.1% 
(± 12.2). The CRASH-CT-Coag score outperformed the 
CRASH-CT score on calibration as assessed by the Brier 
scores (0.122 ± 0.216 vs 0.132 ± 0.202, mean difference 
0.010, 95%CI 0.005–0.019, p = 0.036, respectively). This 
indicates that the new model leads to overall smaller dif-
ferences between the predicted death probabilities and 
the observed outcomes (Fig.  2, panel A). Both scores 
showed the satisfactory results by the H–L test (x2 = 12.8, 
p = 0.118 and x2 = 11.0, p = 0.201, respectively) (Fig.  2, 
panels C and D).
The CRASH-CT-Coag score also had a better dis-
crimination. The AUC-ROC for the new model was 
0.854 ± 0.020 versus 0.813 ± 0.024 for the original one 
(p = 0.014) (Fig. 2, panel B). Also, the mean risk difference 
on predicted death probabilities for those who survived 
and those who did not was higher for the CRASH-CT-
Coag model (29.4%, 95% CI 21.1–39.0 vs 24.4%, 95% CI 
16.3–33.2, p < 0.001). This implies an IDI of 5.0% (95% 
CI 1.3–11.0%), which is the additional difference on pre-
dicted death probabilities between the survivors and the 
dead subjects (Fig. 2, panel A).
Considering the strata of low (< 10%), moderate 
(10–30%) and high (> 30%) risk of death, the CRASH-
CT-Coag model, compared to the original CRASH-CT, 
would yield a global net correct reclassification of 22.9% 
(95% CI 3.8–43.4%) (Table  4). Among the survivors, 
the NRI to a lower risk stratum was 8.5% (95% CI 0.3–
26.9%). Among the dead ones, the NRI to a higher risk 
stratum was 14.4% (95% CI 0.9–22.6%). In other words, 
the CRASH-CT-Coag score had a better performance 
regardless of the outcome. In Fig. 3, the predicted death 
probabilities by the new model were plotted against the 
probability predicted by the original CRASH-CT model. 
The new predicted death probability strata were higher 
on the red area, the same on the white area and lower 
on the green area. Thus, the ideal scenario would be for 
the dead subjects to be on the red area and the survivors 
on the green area. The four discernible groups visually 
shown in Fig. 3 reflect the difference between the models 
underevaluation, which is due to the three dichotomous 
variables (normal or altered platelet count, INR and 
aPTT ratio, which OR are similarly around 2–2.5). 
Case examples are presented in Table  5 to illustrate 
how the adjusted model could impact the predicted out-
come probability.
Discussion
Coagulopathy is common after TBI, and its reported 
incidence may vary from 10% to more than 90%, depend-
ing on the definition, for which there is no consensus 
yet [8, 9]. This disorder may start from minutes to hours 
after TBI and, although most develop it at the first 24 h, 
it may occur up to the fifth-day post-injury and extend 
Table 2 Coagulation parameters
Categorical data are presented as n (%) and continuous data as median (quartiles)
APTT activated partial thromboplastin time, INR international normalized ratio
Variables Total (517) 14-day outcome p value
Dead (118) Alive (399)
Platelets × 105  mm3 178 (137–227) 162 (115–218) 185 (147–228) 0.003
 Platelets < 100,000/mm3 57 (11.3) 26 (22.4) 31 (8.0) < 0.001
Prothrombin time (INR) 1.28 (1.17–1.46) 1.40 (1.25–1.67) 1.25 (1.15–1.40) < 0.001
 INR > 1.2 335 (65.0) 95 (80.5) 240 (60.5) < 0.001
APTT 1.09 (0.97–1.22) 1.19 (1.09–1.47) 1.05 (0.95–1.18) < 0.001
 aPTT > 1.2 140 (27.2) 54 (46.2) 86 (21.6) < 0.001
Table 3 Multivariable logistic regression model for 14-day 
mortality prediction
aPTT activated partial thromboplastin time, CI confidence interval, Coef 
coefficient, INR international normalized ratio, OR odds ratio, SE standard error
Variables Coef SE OR 95% CI p value
CRASH-CT adjusted model
 Platelets < 100,000/
mm3
0.896 0.389 2.45 1.14–5.25 0.021
 INR > 1.2 0.708 0.338 2.03 1.05–3.94 0.036
 aPTT > 1.2 0.917 0.293 2.50 1.41–4.48 0.002
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for more than 72 h in 30% of the cases [10]. It seems to 
be associated with the severity of the injury, rather than 
its location [11, 12]. However, coagulopathy itself exerts 
an independent effect on mortality after TBI [10, 12, 13]. 
Thus, the hypothesis that coagulopathy markers would 
improve the available TBI scores is sound.
We have shown that coagulopathy markers may 
increase the prognostic accuracy of the CRASH-CT 
score, although it performed quite well in our popula-
tion. Each altered parameter, platelet count, INR or 
aPTT ratio, more than doubled the odds of death. Dif-
ferent methodologies were used to assess all components 
Fig. 2 Panel A: Observed outcomes and predicted death probability according to each model. The CRASH-CT-Coag score outperformed the 
CRASH-CT score on calibration (Brier scores 0.122 ± 0.216 vs 0.132 ± 0.202, mean difference 0.010, 95% CI 0.005–0.019, p = 0.036). This indicates 
that the new model leads to overall smaller differences between the predicted death probabilities and the observed outcomes. Also, the mean risk 
difference on predicted death probabilities for those who survived and those who did not was higher for the CRASH-CT-Coag model (29.4%, 95% CI 
21.1–39.0 vs 24.4%, 95% CI 16.3–33.2, p < 0.001). This implies an integrated discrimination improvement (IDI) of 5.0% (95% CI 1.3–11.0%), which is the 
additional difference on predicted death probabilities between the survivors and the dead subjects; Panel B: Receiver operating characteristic (ROC) 
curve analysis. The CRASH-CT-Coag score also had a better discrimination. The AUC-ROC for the new model was 0.854 ± 0.020 vs 0.813 ± 0.024 for 
the original one (p = 0.014); Panels C and D: Observed and predicted death probabilities by estimated risk deciles. Both scores showed satisfactory 
results by the H–L test (x2 = 12.8, p = 0.118 and x2 = 11.0, p = 0.201, respectively)
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of accuracy and were consistent on showing the new 
model superiority regarding discrimination, calibration 
and clinical utility. The parameters analyzed are inex-
pensive and usually routinely measured on trauma and 
intensive care patients. Also, the cutoffs used for the 
dichotomous classification (altered or normal) are inter-
nationally standardized and well-grounded on clinical 
practice—rather than artificial cutoffs to maximize statis-
tical significance. To our knowledge, this is the one of the 
most comprehensive evaluations of routine coagulopathy 
markers for TBI prognostication. Yuan et  al. [14] have 
also demonstrated that the addition of the coagulation 
test results (INR and aPTT) to a newly developed multi-
variable model including age, neurological examination, 
imaging and glucose can improve its predictive ability, 
but they have not compared it against a previously vali-
dated score (as the CRASH or the IMPACT models).
Some critical care scores do include some of these 
coagulopathy indicators as risk markers or worse out-
come predictors. Moreover, although the original 
CRASH score did not evaluate laboratory variables, the 
international mission for prognosis and analysis of clini-
cal trials in traumatic brain injury (IMPACT) original 
study analysis—another well-grounded TBI prognostic 
tool—was significant for platelets and INR as predictors 
of outcome [15]. Ultimately, platelets and INR were not 
included in the final IMPACT score because these meas-
ures were available on less than 20% and 10%, respec-
tively, of the total study sample. The aPTT values were 
not analyzed in the IMPACT study.
The above relates to the first limitation to be noted in 
our study. The IMPACT extended model includes vari-
ables that were not fully addressed by the protocol of 
this study and hypoxia and glucose were not available at 
admission for almost half of the sample. Thus, we could 
not perform a similar analysis with adjustment for the 
IMPACT extended model. However, the IMPACT model 
was developed based on patients from high-income 
countries, whereas the CRASH data were mainly col-
lected from low- and middle-income ones. It has been 
shown that the IMPACT model may not fit the CRASH 
data so well [16]. Even though we only analyzed the early 
14-day vital status, this is a trustworthy outcome and 
robust against rehabilitation capacity shortages, which is 
still a problem in middle-income countries and impacts 
the long-term clinical results. Another constraint is the 
literature heterogeneity regarding the definition of coag-
ulopathy. For instance, coagulopathy incidence variation 
has been attributed to differences in study designs, injury 
diversity, different time points for testing of coagulation 
parameters and the absence of a universally recognized 
definition of coagulopathy [8, 9]. As we said, the selected 
cutoffs for platelet count, INR and aPTT ratio are stand-
ard and common on clinical practice, but we recognize 
that any dichotomization of a continuous variable may 
carry some bias and may be criticized. The dynamic 
nature of TBI poses additional challenges on that mat-
ter. Lastly, although the incremental prognostic value of 
coagulopathy was consistent across different methods of 
analysis, an external validation of this proposal of prog-
nostic model extension is crucial for its endorsement 
and clinical application. Additional tests for the evalua-
tion of the coagulation system—enzymatic processes, 
Table 4 Stratified predicted death probability according 
to each model and outcomes
a Patients correctly reclassified by the CRASH-CT-Coag model
b Patients wrongly reclassified by the CRASH-CT-COag model
CRASH-CT-Coag
< 10% 10–30% > 30%
Fourteen-day outcome: dead
 CRASH-CT
  < 10% 2 3 a 0a
  10–30% 5b 16 3a
  > 30% 0b 8b 60
Fourteen-day outcome: alive
 CRASH-CT
  < 10% 103 19b 1b
  10–30% 84a 49 10b
  > 30% 1a 37a 37
Fig. 3 Predicted death probabilities for the original and new models 
according to risk strata and 14-day outcome. The new predicted 
death probability strata are higher on the red area, the same on the 
white area and lower on the green area. The four discernible groups 
visually seen reflect the difference between the models under evalu-
ation, which is due to the three dichotomous variables (normal 
or altered platelet count, INR and aPTT ratio, which odds ratio are 
similarly around 2–2.5)
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fibrinolysis and platelets function—are becoming more 
widely available (e.g., fibrinogen and thromboelastogra-
phy), and these may gain further relevance on coagulopa-
thy management and outcome prognosis.
Opportunities for updating the CRASH and IMPACT 
models may be brought in the near future by notewor-
thy studies, including the Collaborative European Neuro-
Trauma Effectiveness Research in Traumatic Brain Injury 
(CENTER‐TBI) study, Transforming Research and Clini-
cal Knowledge in TBI (TRACK‐TBI) dataset and Col-
laborative REsearch on ACute Traumatic Brain Injury 
in intensiVe Care Medicine in Europe (CREACTIVE) 
[17–19].
Conclusion
The addition of platelet count, INR and aPTT, interpreted 
as early markers of coagulopathy, to the CRASH-CT 
score increased its accuracy, with better discrimination, 
calibration and clinical utility. Additional studies are 
required to externally validate this finding and further 
investigate its implications for TBI management. Moreo-
ver, this result underscores the need for further investiga-
tion of the coagulopathy role on TBI outcomes.
Abbreviations
aPTT: Activated partial thromboplastin time; AUC-ROC: Area under the 
receiver operating characteristic curve; CENTER‐TBI: Collaborative European 
NeuroTrauma Effectiveness Research in Traumatic Brain Injury study; CREAC-
TIVE: Collaborative REsearch on ACute Traumatic Brain Injury in intensiVe Care 
Medicine in Europe; CRASH: Corticosteroid randomization after significant 
head injury; CT: Computed tomography; GCS: Glasgow coma scale; HC/
FMUSP: Hospital das Clínicas da Faculdade de Medicina da Universidade de 
São Paulo; ICU: Intensive care unit; IDI: Integrated discrimination improvement; 
IMPACT : International mission for prognosis and analysis of clinical trials in 
traumatic brain injury; INR: International normalized ratio; NRI: Net reclassifica-
tion index; TBI: Traumatic brain injury; TRACK‐TBI: Transforming research and 
clinical knowledge in TBI; TRIPOD: Transparent reporting of a multivariable 
prediction model for individual prognosis or diagnosis.
Author details
1 Division of Neurosurgery, Department of Neurology, Hospital das Clínicas da 
Faculdade de Medicina, University of São Paulo, Dr. Enéas Carvalho de Aguiar 
Avenue, 255, São Paulo 05403-000, Brazil. 2 Division of Neurosurgery, Depart-
ment of Clinical Neurosciences, Addenbrooke’s Hospital, University of Cam-
bridge, Cambridge, UK. 3 NIHR Global Health Research Group on Neurotrauma, 
University of Cambridge, Cambridge, UK. 
Author Contributions
Drs. Solla, Amorim and Paiva had full access to all data in the study and take 
responsibility for the integrity of the data and the accuracy of the data analy-
sis. Solla, Amorim and Paiva participated in concept and design. Solla, Amorim, 
Kolias, Hutchinson, Andrade, Teixeira and Paiva contributed in acquisition, 
analysis or interpretation of data. Solla conducted the statistical analysis and 
drafted the manuscript. Solla, Amorim, Kolias, Hutchinson, Andrade, Teixeira 
and Paiva participated in critical revision of the manuscript for important 
intellectual content. Amorim and Paiva obtained the funding. Paiva, Amorim, 
Andrade, Kolias and Hutchinson contributed in supervision.
Source of Support
This research was partially funded by the National Council for Scientific and 
Technological Development (CNPq), Brazil. Drs Solla, Kolias, Hutchinson 
and Paiva are supported by the NIHR Global Health Research Group on 
Neurotrauma, which was commissioned by the National Institute for Health 
Research (NIHR) using UK aid from the UK Government (project 16/137/105). 
The views expressed in this publication are those of the author(s) and not 
necessarily those of the NIHR or the Department of Health and Social Care. 
Angelos Kolias is supported by a Clinical Lectureship, School of Clinical 
Table 5 Case examples, predicted death probabilities by each model and observed outcomes
aPTT activated partial thromboplastin time, CT computed tomography, GCS glasgow coma scale, INR international normalized ratio, VT ventricle
Model variables Case 1 Case 4 Case 5 Case 3 Case 2 Case 6 Case 7
Age 31 66 39 80 69 46 22
Admission GCS 13 7 10 10 14 6 4
Reactive pupils Both One Both Both Both Both Both
Major extracranial injury No Yes Yes Yes Yes No Yes
Imaging (head CT)
 Petechial hemorrhages No No No Yes No No No
 Basal cisterns or III VT obliteration No No Yes No No No No
 Subarachnoid bleeding Yes Yes Yes Yes Yes Yes Yes
 Midline shift No No Yes No No No No
 Hematoma Yes Yes Yes Yes Yes No Yes
Coagulation
 Platelets (/mm3) 18.000 115.000 205.000 83.000 17.000 112.000 189.000
 INR 1.33 1.18 1.06 2.53 1.48 1.02 1.10
 aPTT 1.50 0.96 1.10 1.23 1.90 0.80 0.97
Predicted 14-day death probability (%)
 CRASH-CT 4.7 51.7 28.1 45.7 13.3 19.3 32.0
 CRASH-CT-Coag 27.2 22.0 8.4 72.4 36.1 5.7 9.9
Fourteen-day outcome Dead Alive Alive Dead Dead Alive Alive
138
Medicine, University of Cambridge and the Royal College of Surgeons of 
England. Peter Hutchinson is supported by a Research Professorship from the 
NIHR, the NIHR Cambridge Biomedical Research Centre, a European Union 
Seventh Framework Program grant (CENTER-TBI; grant no. 602150), and the 
Royal College of Surgeons of England.
Conflict of interest
Davi J. Fontoura Solla: Dr. Solla reports grants and non-financial support from 
National Institute for Health Research (NIHR), during the conduct of the study. 
Robson Luis Oliveira de Amorim: Dr. Amorim reports grants from National 
Council for Scientific and Technological Development (CNPq), Brazil, during 
the conduct of the study. Angelos G. Kolias: Dr. Kolias reports grants and non-
financial support from National Institute for Health Research (NIHR), grants 
and non-financial support from School of Clinical Medicine, University of 
Cambridge, grants and non-financial support from Royal College of Surgeons 
of England, during the conduct of the study. Peter J. Hutchinson: Dr. Hutchin-
son reports grants and non-financial support from National Institute for Health 
Research (NIHR), grants and non-financial support from NIHR Cambridge 
Biomedical Research Centre, grants and non-financial support from Royal Col-
lege of Surgeons of England, grants from European Union Seventh Framework 
Program, during the conduct of the study. Almir Ferreira de Andrade: Dr. 
Andrade has nothing to disclose. Manoel Jacobsen Teixeira: Dr. Jacobsen-
Teixeira has nothing to disclose. Wellingson Silva Paiva: Dr. Paiva reports grants 
and non-financial support from National Institute for Health Research (NIHR), 
during the conduct of the study.
Ethical Approval
We confirm the adherence to ethical guidelines—this study protocol was 
approved by the local ethics committee (Comissão de Análise de Projetos de 
Pesquisa—CAPPesq, HC/FMUSP, Protocol Number 00119/10). The Transpar-
ent Reporting of a multivariable prediction model for Individual Prognosis Or 
Diagnosis (TRIPOD) Statement was followed for this study report.
Open Access
This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction 
in any medium or format, as long as you give appropriate credit to the original 
author(s) and the source, provide a link to the Creative Commons licence, and 
indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in the 
article’s Creative Commons licence and your intended use is not permitted 
by statutory regulation or exceeds the permitted use, you will need to obtain 
permission directly from the copyright holder. To view a copy of this licence, 
visit http://creat iveco mmons .org/licen ses/by/4.0/.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Published online: 22 May 2020
References
 1. Lingsma HF, Roozenbeek B, Steyerberg EW, Murray GD, Maas AIR. Early 
prognosis in traumatic brain injury: from prophecies to predictions. 
Lancet Neurol. 2010;9(5):543–54.
 2. Crash MRC, Collaborators T. Predicting outcome after traumatic brain 
injury: practical prognostic models based on large cohort of international 
patients. BMJ. 2008;336(7641):425–9.
 3. Steyerberg EW, Mushkudiani N, Perel P, et al. Predicting outcome after 
traumatic brain injury: development and international validation of 
prognostic scores based on admission characteristics. PLoS Med. 
2008;5(8):e165 (discussion e165).
 4. Chhabra G, Sharma S, Subramanian A, Agrawal D, Sinha S, Mukhopad-
hyay AK. Coagulopathy as prognostic marker in acute traumatic brain 
injury. J Emerg Trauma Shock. 2013;6(3):180–5.
 5. Talving P, Benfield R, Hadjizacharia P, Inaba K, Chan LS, Demetriades D. 
Coagulopathy in severe traumatic brain injury: a prospective study. J 
Trauma. 2009;66(1):55–61 (discussion 61-2).
 6. Raj R, Siironen J, Kivisaari R, et al. External validation of the international mis-
sion for prognosis and analysis of clinical trials model and the role of markers 
of coagulation. Neurosurgery. 2013;73(2):305–11 (discussion 311).
 7. Brain Trauma Foundation, American Association of Neurological Sur-
geons, Congress of Neurological Surgeons. Guidelines for the manage-
ment of severe traumatic brain injury. J Neurotrauma. 2007;24(Suppl 
1):S1–S106.
 8. Harhangi BS, Kompanje EJO, Leebeek FWG, Maas AIR. Coagulation disor-
ders after traumatic brain injury. Acta Neurochir (Wien). 2008;150(2):165–
75 (discussion 175).
 9. Laroche M, Kutcher ME, Huang MC, Cohen MJ, Manley GT. Coagulopathy 
after traumatic brain injury. Neurosurgery. 2012;70(6):1334–455.
 10. Lustenberger T, Talving P, Kobayashi L, et al. Time course of coagulopathy 
in isolated severe traumatic brain injury. Injury. 2010;41(9):924–8.
 11. Genét GF, Johansson PI, Meyer MAS, et al. Trauma-induced coagulopathy: 
standard coagulation tests, biomarkers of coagulopathy, and endothe-
lial damage in patients with traumatic brain injury. J Neurotrauma. 
2013;30(4):301–6.
 12. de Oliveira Manoel AL, Neto AC, Veigas PV, Rizoli S. Traumatic brain injury 
associated coagulopathy. Neurocrit Care. 2015;22(1):34–44.
 13. Wafaisade A, Lefering R, Tjardes T, et al. Acute coagulopathy in isolated 
blunt traumatic brain injury. Neurocrit Care. 2010;12(2):211–9.
 14. Yuan Q, Yu J, Wu X, et al. Prognostic value of coagulation tests for in-
hospital mortality in patients with traumatic brain injury. Scand J Trauma 
Resusc Emerg Med. 2018;26(1):3.
 15. Murray GD, Butcher I, McHugh GS, et al. Multivariable prognostic analysis 
in traumatic brain injury: results from the IMPACT study. J Neurotrauma. 
2007;24(2):329–37.
 16. Gao J, Zheng Z. Development of prognostic models for patients 
with traumatic brain injury: a systematic review. Int J Clin Exp Med. 
2015;8(11):19881–5.
 17. CENTER-TBI. Collaborative European neurotrauma effectiveness research 
in TBI—ClinicalTrials.gov Identifier: NCT02210221.
 18. TRACK-TBI. Transforming research and clinical knowledge in traumatic 
brain injury—ClinicalTrials.gov Identifier: NCT02119182.
 19. CREACTIVE. Collaborative REsearch on ACute Traumatic Brain Injury 
in intensiVe Care Medicine in Europe—ClinicalTrials.gov Identifier: 
NCT02004080.
